Structural Basis of Inhibition of Human Insulin-Regulated Aminopeptidase (IRAP) by Aryl Sulfonamides

Sudarsana Reddy Vanga, Jonas Sävmarker, Leelee Ng, Mats Larhed, Mathias Hallberg, Johan Åqvist, Anders Hallberg, Siew Yeen Chai, Hugo Gutiérrez-De-Terán

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Abstract

The insulin-regulated aminopeptidase (IRAP) is a membrane-bound zinc metallopeptidase with many important regulatory functions. It has been demonstrated that inhibition of IRAP by angiotensin IV (Ang IV) and other peptides, as well as more druglike inhibitors, improves cognition in several rodent models. We recently reported a series of aryl sulfonamides as small-molecule IRAP inhibitors and a promising scaffold for pharmacological intervention. We have now expanded with a number of derivatives, report their stability in liver microsomes, and characterize the activity of the whole series in a new assay performed on recombinant human IRAP. Several compounds, such as the new fluorinated derivative 29, present submicromolar affinity and high metabolic stability. Starting from the two binding modes previously proposed for the sulfonamide scaffold, we systematically performed molecular dynamics simulations and binding affinity estimation with the linear interaction energy method for the full compound series. The significant agreement with experimental affinities suggests one of the binding modes, which was further confirmed by the excellent correlation for binding affinity differences between the selected pair of compounds obtained by rigorous free energy perturbation calculations. The new experimental data and the computationally derived structure-activity relationship of the sulfonamide series provide valuable information for further lead optimization of novel IRAP inhibitors.

Original languageEnglish
Pages (from-to)4509-4521
Number of pages13
JournalACS Omega
Volume3
Issue number4
DOIs
Publication statusPublished - 1 Jan 2018

Cite this

Vanga, S. R., Sävmarker, J., Ng, L., Larhed, M., Hallberg, M., Åqvist, J., ... Gutiérrez-De-Terán, H. (2018). Structural Basis of Inhibition of Human Insulin-Regulated Aminopeptidase (IRAP) by Aryl Sulfonamides. ACS Omega, 3(4), 4509-4521. https://doi.org/10.1021/acsomega.8b00595
Vanga, Sudarsana Reddy ; Sävmarker, Jonas ; Ng, Leelee ; Larhed, Mats ; Hallberg, Mathias ; Åqvist, Johan ; Hallberg, Anders ; Chai, Siew Yeen ; Gutiérrez-De-Terán, Hugo. / Structural Basis of Inhibition of Human Insulin-Regulated Aminopeptidase (IRAP) by Aryl Sulfonamides. In: ACS Omega. 2018 ; Vol. 3, No. 4. pp. 4509-4521.
@article{e167bc75db8947c094649978254c83e6,
title = "Structural Basis of Inhibition of Human Insulin-Regulated Aminopeptidase (IRAP) by Aryl Sulfonamides",
abstract = "The insulin-regulated aminopeptidase (IRAP) is a membrane-bound zinc metallopeptidase with many important regulatory functions. It has been demonstrated that inhibition of IRAP by angiotensin IV (Ang IV) and other peptides, as well as more druglike inhibitors, improves cognition in several rodent models. We recently reported a series of aryl sulfonamides as small-molecule IRAP inhibitors and a promising scaffold for pharmacological intervention. We have now expanded with a number of derivatives, report their stability in liver microsomes, and characterize the activity of the whole series in a new assay performed on recombinant human IRAP. Several compounds, such as the new fluorinated derivative 29, present submicromolar affinity and high metabolic stability. Starting from the two binding modes previously proposed for the sulfonamide scaffold, we systematically performed molecular dynamics simulations and binding affinity estimation with the linear interaction energy method for the full compound series. The significant agreement with experimental affinities suggests one of the binding modes, which was further confirmed by the excellent correlation for binding affinity differences between the selected pair of compounds obtained by rigorous free energy perturbation calculations. The new experimental data and the computationally derived structure-activity relationship of the sulfonamide series provide valuable information for further lead optimization of novel IRAP inhibitors.",
author = "Vanga, {Sudarsana Reddy} and Jonas S{\"a}vmarker and Leelee Ng and Mats Larhed and Mathias Hallberg and Johan {\AA}qvist and Anders Hallberg and Chai, {Siew Yeen} and Hugo Guti{\'e}rrez-De-Ter{\'a}n",
year = "2018",
month = "1",
day = "1",
doi = "10.1021/acsomega.8b00595",
language = "English",
volume = "3",
pages = "4509--4521",
journal = "ACS Omega",
issn = "2470-1343",
publisher = "American Chemical Society",
number = "4",

}

Vanga, SR, Sävmarker, J, Ng, L, Larhed, M, Hallberg, M, Åqvist, J, Hallberg, A, Chai, SY & Gutiérrez-De-Terán, H 2018, 'Structural Basis of Inhibition of Human Insulin-Regulated Aminopeptidase (IRAP) by Aryl Sulfonamides', ACS Omega, vol. 3, no. 4, pp. 4509-4521. https://doi.org/10.1021/acsomega.8b00595

Structural Basis of Inhibition of Human Insulin-Regulated Aminopeptidase (IRAP) by Aryl Sulfonamides. / Vanga, Sudarsana Reddy; Sävmarker, Jonas; Ng, Leelee; Larhed, Mats; Hallberg, Mathias; Åqvist, Johan; Hallberg, Anders; Chai, Siew Yeen; Gutiérrez-De-Terán, Hugo.

In: ACS Omega, Vol. 3, No. 4, 01.01.2018, p. 4509-4521.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Structural Basis of Inhibition of Human Insulin-Regulated Aminopeptidase (IRAP) by Aryl Sulfonamides

AU - Vanga, Sudarsana Reddy

AU - Sävmarker, Jonas

AU - Ng, Leelee

AU - Larhed, Mats

AU - Hallberg, Mathias

AU - Åqvist, Johan

AU - Hallberg, Anders

AU - Chai, Siew Yeen

AU - Gutiérrez-De-Terán, Hugo

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The insulin-regulated aminopeptidase (IRAP) is a membrane-bound zinc metallopeptidase with many important regulatory functions. It has been demonstrated that inhibition of IRAP by angiotensin IV (Ang IV) and other peptides, as well as more druglike inhibitors, improves cognition in several rodent models. We recently reported a series of aryl sulfonamides as small-molecule IRAP inhibitors and a promising scaffold for pharmacological intervention. We have now expanded with a number of derivatives, report their stability in liver microsomes, and characterize the activity of the whole series in a new assay performed on recombinant human IRAP. Several compounds, such as the new fluorinated derivative 29, present submicromolar affinity and high metabolic stability. Starting from the two binding modes previously proposed for the sulfonamide scaffold, we systematically performed molecular dynamics simulations and binding affinity estimation with the linear interaction energy method for the full compound series. The significant agreement with experimental affinities suggests one of the binding modes, which was further confirmed by the excellent correlation for binding affinity differences between the selected pair of compounds obtained by rigorous free energy perturbation calculations. The new experimental data and the computationally derived structure-activity relationship of the sulfonamide series provide valuable information for further lead optimization of novel IRAP inhibitors.

AB - The insulin-regulated aminopeptidase (IRAP) is a membrane-bound zinc metallopeptidase with many important regulatory functions. It has been demonstrated that inhibition of IRAP by angiotensin IV (Ang IV) and other peptides, as well as more druglike inhibitors, improves cognition in several rodent models. We recently reported a series of aryl sulfonamides as small-molecule IRAP inhibitors and a promising scaffold for pharmacological intervention. We have now expanded with a number of derivatives, report their stability in liver microsomes, and characterize the activity of the whole series in a new assay performed on recombinant human IRAP. Several compounds, such as the new fluorinated derivative 29, present submicromolar affinity and high metabolic stability. Starting from the two binding modes previously proposed for the sulfonamide scaffold, we systematically performed molecular dynamics simulations and binding affinity estimation with the linear interaction energy method for the full compound series. The significant agreement with experimental affinities suggests one of the binding modes, which was further confirmed by the excellent correlation for binding affinity differences between the selected pair of compounds obtained by rigorous free energy perturbation calculations. The new experimental data and the computationally derived structure-activity relationship of the sulfonamide series provide valuable information for further lead optimization of novel IRAP inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=85046031873&partnerID=8YFLogxK

U2 - 10.1021/acsomega.8b00595

DO - 10.1021/acsomega.8b00595

M3 - Article

VL - 3

SP - 4509

EP - 4521

JO - ACS Omega

JF - ACS Omega

SN - 2470-1343

IS - 4

ER -

Vanga SR, Sävmarker J, Ng L, Larhed M, Hallberg M, Åqvist J et al. Structural Basis of Inhibition of Human Insulin-Regulated Aminopeptidase (IRAP) by Aryl Sulfonamides. ACS Omega. 2018 Jan 1;3(4):4509-4521. https://doi.org/10.1021/acsomega.8b00595